Molecular Biology of Plasminogen Activators: What Are the Clinical Implications of Drug Design?
- 1 December 1996
- journal article
- research article
- Published by Elsevier in The American Journal of Cardiology
- Vol. 78 (12) , 2-7
- https://doi.org/10.1016/s0002-9149(96)00736-9
Abstract
No abstract availableKeywords
This publication has 36 references indexed in Scilit:
- Effect of Infarct Artery Patency on Prognosis After Acute Myocardial InfarctionCirculation, 1995
- The Effects of Tissue Plasminogen Activator, Streptokinase, or Both on Coronary-Artery Patency, Ventricular Function, and Survival after Acute Myocardial InfarctionNew England Journal of Medicine, 1993
- Prehospital thrombolysis: Beneficial effects of very early treatment on infarct size and left ventricular functionJournal of the American College of Cardiology, 1993
- Prehospital-Initiated vs Hospital-Initiated Thrombolytic TherapyJAMA, 1993
- Late Assessment of Thrombolytic Efficacy (LATE) study with alteplase 6-24 hours after onset of acute myocardial infarctionThe Lancet, 1993
- TIMI perfusion grade 3 but not grade 2 results in improved outcome after thrombolysis for myocardial infarction. Ventriculographic, enzymatic, and electrocardiographic evidence from the TEAM-3 Study.Circulation, 1993
- Impact of early perfusion status of the infarct-related artery on short-term mortality after thrombolysis for acute myocardial infarction: Retrospective analysis of four german multicenter studiesJournal of the American College of Cardiology, 1993
- Consequences of reocclusion after successful reperfusion therapy in acute myocardial infarction. TAMI Study Group.Circulation, 1990
- Six- and twelve-month follow-up of the phase I thrombolysis in myocardial infarction (TIMI) trialThe American Journal of Cardiology, 1988
- Beneficial effects of intracoronary thrombolysis up to eighteen hours after onset of pain in evolving myocardial infarctionAmerican Heart Journal, 1982